flumazenil

(redirected from Romazicon)

flumazenil

 [floo-ma´zĕ-nil″]
a benzodiazepine agonist that competitively binds to receptor sites in the central nervous system; used to reverse the effects of benzodiazepines after sedation, general anesthesia, or overdose.

flu·ma·ze·nil

(flū'mā-zē-nil),
A benzodiazepine with antagonist properties at the benzodiazepine recognition site of the benzodiazepine-GABA-chloride channel complex. Used as a treatment for overdose with benzodiazepine-type central nervous system depressants, or for controlled reversal of anesthesia induced by such agents.

flumazenil

/flu·ma·ze·nil/ (floo-ma´zĕ-nil″) a benzodiazepine agonist used to reverse the effects of benzodiazepines after sedation, general anesthesia, or overdose.

flu·ma·ze·nil

(flū'mā-zē'nil)
Benzodiazepine with antagonist properties at the benzodiazepine recognition site of the benzodiazepine gamma-aminobutyric acid-chloride channel complex. Used to treat overdose with benzodiazepine-type central nervous system depressants or controlled reversal of anesthesia induced by such agents.

flumazenil

A drug that opposes the action of BENZODIAZEPINE drugs and can be used to reverse their sedating effect. A brand name is Anexate.

flu·ma·ze·nil

(flū'mā-zē'nil)
Benzodiazepine with antagonist properties used to treat overdose with benzodiazepine-type central nervous system depressants, or for controlled reversal of anesthesia induced by such agents.

flumazenil

(floo´mazənil´),
n brand name: Romazicon;
drug class: benzodiazepine receptor antagonist;
action: antagonizes actions of benziodiazepines on the central nervous system;
use: reversal of sedative effects of benzodiazepines.

flumazenil

a benzodiazepine antagonist.
References in periodicals archive ?
Orders for antidotes (Benadryl, Narcan, Romazicon, Vitamin K, anti-emetics, anti-diarrheals) 2.
Accupril - Agrylin - Axid - Biaxin - Celexa - Cipro - Difl ucan - Duragesic - Effexor - Flonase - Floxin/Occufl ox - Glucophage XR - Glucotrol XL - Glucovance - Lotensin - Metaglip - Mobic - Monopril - Novantrone - Paraplatin - Paxil - Pravachol - Proscar - Retrovir - Rocephin - Romazicon - Tambocor - Ultram - Zaditor - Zestril/Prinivil - Zithromax - Zocor - Zofran - Zoloft
Roche launched and achieved market share leadership with Xenical, Tamiflu, and Valcyte, as well as maintaining leadership positions with Rocephin, Versed, Demadex, Romazicon, Accutane, Soriatane, and CellCept during his tenure.
An injectable solution, Romazicon is indicated for rapid reversal of the sedative effects of benzodiazepines, which are used for conscious sedation or as part of general anesthesia for an estimated 31 million surgical, diagnostic and therapeutic procedures annually.
Romazicon is part of a unique therapeutic category, and is the only drug in its class.
Romazicon allows the anesthesiologist to restore consciousness rapidly and smoothly.
A pulmonary patient treated with Romazicon, for example, is able to respond to the physician's instructions to participate in deep breathing, to cough and to talk.
Clinical trials show that Romazicon is generally well tolerated by patients.
Romazicon is contraindicated in certain patients in whom antagonism of the benzodiazepine has been associated with the occurrence of seizures.
Romazicon is contraindicated in patients showing signs of serious cyclic antidepressant overdose, patients who receive benzodiazepines to control potentially life-threatening conditions and patients hypersensitive to benzodiazepines or flumazenil.